Array's

Yet while the company saved on payroll, there were plenty of additional operational costs, admits Matthew Guthrie, Array's president.

Putting Prisoners To Work 2008

This drug discovery capability, which was seen by many as the most defining criterion in Array's value, does not seem to considered by the evaluators of biotech firms.

unknown title 2011

The question is: At Array's current market capitalization, is its stock undervalued, overvalued, or fairly valued?

unknown title 2011

Critics' believe that Array's partnered and proprietary totally owned drugs are still in early clinical trials;

unknown title 2011

That's why Ariad's market capitalization has reached over $1.3 Billion, while Array's market cap is as low as $125 million.

unknown title 2011

To reach an answer to this question one has to see how the market is evaluating similar firms when they were at the same stages of their drug development and how their evaluations proceeded when these firms reached beyond Array's drug development stage.

unknown title 2011

Among other negatives, some critics voiced their concern that the small molecule nature of Array's cancer products are not what the pharmaceutical companies are striving for, in addition to the potential grave side effects, especially when the therapeutic small molecules aim at multiple targets!

unknown title 2011

Prior to this milestone, Ariad's stock price was stagnant and the firm's market value was as low as Array's current market value.

unknown title 2011

Array's friends have expressed enthusiasm for the news, announcing that Array is cutting spending.

unknown title 2011

The reality that we have to take, or leave, is that Array's current stock price, undervalued as it might be, is the fixed price of what could be predicted as an excellent future biotech firm.

unknown title 2011